Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Summary

The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Eligibility

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form;
* Male or female 18\~75 years of age;
* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
* Life expectancy ≥ 3 months;
* Histologically or cytologically confirmed Small Cell Lung Cancer.

Exclusion Criteria:

* Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Conditions3

Interventions2

Related trials

• A Multi-Arm, Platform Trial For Relapsed Neuroblastoma — University of Birmingham
• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) — GlaxoSmithKline
• A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Qilu Pharmaceutical Co., Ltd.
• ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer — Hansoh BioMedical R&D Company
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors — Gustave Roussy, Cancer Campus, Grand Paris
• HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer — Hansoh BioMedical R&D Company
• High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed — Eye & ENT Hospital of Fudan University
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC — Luye Pharma Group Ltd.

Browse More Trials